Anixa Biosciences is trading 7.6% lower at $2.68 in pre-market; no direct catalyst was identified. - The October 9 close was $2.90; supplied price context shows a recent pullback from $3.02 on October 6. - No October 12 announcement appears on the investor-relations release list. Its latest listed release, October 5, reported stable disease in one patient in its ovarian cancer CAR-T trial; that update does not clearly explain the drop.